When David Fajgenbaum and his colleagues launched the drug repurposing non-profit Every Cure, they chose a path that challenged the traditional research model.
Source: US Top News and Analysis
Related Posts
Arm stock pops 6% as CEO Haas issues $15 billion revenue expectation for new chip
Arm unveiled its first in-house chip on Tuesday at an event in San Francisco, with…
Retail firms warn of price hikes if Iran war extends for months
Fashion retailer Next has accounted for millions in additional costs likely to arise from the…
This AI marketing stock is a top gainer today. Goldman says there’s much more to go
Braze rallied as much as 25% before the bell on Wednesday, making it the top…